Prostate cancer is a hormone-driven disease and its tumor cell growth highly relies on
increased androgen receptor (AR) signaling. Therefore, targeted therapy directed against …

Simple Summary This review summarizes recent advances in the nuclear medicine
theranostic approach. It covers the repurposing of historical radiotracers for new indications …

The androgen receptor (AR) signaling inhibitor enzalutamide (enza) is one of the principal
treatments for metastatic castration-resistant prostate cancer (CRPC). Several emergent …

Neuroendocrine tumors of the prostate are rare and encompass a group of entities that are
classified based on a combination of morphological and immunohistochemical features …

Background Although most patients with prostate cancer (PC) respond to initial androgen
deprivation therapy (ADT), castration‐resistant disease invariably develops. Progression to …

Inferring gene regulatory networks (GRNs) from single-cell RNA-seq (scRNA-seq) data is an
important computational question to find regulatory mechanisms involved in fundamental …

Abstract Treatment-related neuroendocrine prostate cancer is a distinctive category of
prostate cancer that arises after intensive suppression of the androgen receptor by next …

Aim Clinicopathologic characterisation of a contemporary series of neuroendocrine (NE)
differentiation in the setting of prostatic carcinoma (PCa) was examined. Methods and …

Background Amphicrine prostate carcinoma (AMPC) is a poorly defined subset of prostate
cancer in which cells co‐express luminal prostate epithelial and neuroendocrine markers …

The classification of tumors into subtypes, characterized by phenotypes determined by
specific differentiation pathways, aids diagnosis and directs therapy towards targeted …